Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Epithelial Ovarian Cancer Market?

The market for epithelial ovarian cancer has seen a swift expansion in recent times. The forecast predicts an increase from $2.08 billion in 2024 to $2.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.0%. The growth during the previous period was driven by factors such as surging demand for individualized cancer therapies, an escalation in global healthcare spending, an increasing preference for minimally invasive procedures, a growing number of ovarian cancer survivors, a higher demand for gene therapies, and an uptick in the need for palliative care services.

Rapid expansion is anticipated for the epithelial ovarian cancer market size in the coming years, with a projection to reach $4.36 billion by 2029, courtesy of a compound annual growth rate (CAGR) of 16.0%. This expected growth during the forecast period can be associated with factors regarding the increasing number of ovarian cancer cases, the aging population, heightened awareness about ovarian cancer, enhancements in cancer research funding, and the rise of government initiatives to counteract cancer. Key trends expected within the forecast period encompass developments in medical imaging technology, the launch of innovative molecular diagnostic tools, partnerships amongst pharmaceutical companies, quick adoption of AI and machine learning in diagnostic procedures, and extended use of robotic surgeries.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp

What Core Drivers Are Expected To Influence The Epithelial Ovarian Cancer Market?

The epithelial ovarian cancer market is projected to grow, fueled by the rising incidence of ovarian cancer. This particular type of cancer, which originates primarily in the ovary’s surface-covering epithelial cells, is seeing a rise in prevalence due to factors such as an aging demographic, heightened awareness, increased detection rates, and lifestyle and genetic variables. Therapeutic intervention for epithelial ovarian cancer is crucial, as it represents the most pervasive and lethal form of ovarian cancer, with therapies aimed at eliminating malignant cells to enhance survival rates and patient prognosis. In February 2024, the Canada-based World Ovarian Cancer Coalition, a non-profit entity, predicted that the global count of women diagnosed with ovarian cancer would witness a surge of over 55% by 2050, tipping the scales at 503,448. Yearly fatalities from ovarian cancer are projected to escalate to 350,956, indicating a roughly 70% upturn from 2022. Consequently, the escalating occurrence of ovarian cancer is anticipated to fuel the growth of the epithelial ovarian cancer market in the future.

What Are The Main Segment Classifications In The Epithelial Ovarian Cancer Market?

The epithelial ovarian cancermarket covered in this report is segmented –

1) By Type Of Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Hormonal Therapy; Surgery

2) By Drug Class: Platinum-based Chemotherapy Drugs; Poly(ADP-ribose) Polymerase Inhibitors; Bevacizumab; Chemotherapeutic Agents

3) By Stage Of Cancer: Early Stage; Advanced Stage

4) By Diagnosis Method: Imaging; Biopsy; Blood Tests

5) By End User: Hospitals; Clinics; Diagnostic Laboratories

Subsegments:

1) By Chemotherapy: Platinum-Based Chemotherapy; Non-Platinum Chemotherapy; Combination Chemotherapy

2) By Targeted Therapy: Monoclonal Antibodies; PARP Inhibitors; Angiogenesis Inhibitors; Other Targeted Agents

3) By Immunotherapy: Checkpoint Inhibitors; Cancer Vaccines; Adoptive T-Cell Therapy

4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Progestins

5) By Surgery: Debulking Surgery; Oophorectomy; Hysterectomy; Other Surgical Procedures

How Are Industry Trends Steering The Expansion Of The Epithelial Ovarian Cancer Market?

Key players in the epithelial ovarian cancer market are concentrating their efforts on pioneering novel treatment methods, such as FRα-directed antibody-drug conjugates (ADCs). These treatments are devised to specifically target the folate receptor-alpha overexpressed on cancer cells, delivering powerful cytotoxic substances while sparing healthy tissues. In essence, an FRα-directed antibody-drug conjugate (ADC) couples a folate receptor-alpha (FRα) specific antibody to a cytotoxic substance, consequently guiding the drug directly to cancer cells expressing this receptor. For example, in November 2024, biopharmaceutical firm AbbVie Inc., based in the US, secured approval from the European Commission for their drug ELAHERE (mirvetuximab soravtansine). This targeted treatment is intended for adult patients with FRα positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE constitutes a new potent treatment alternative for patients who have undergone up to three previous systemic treatments. Aligning with a biomarker found in roughly one-third of ovarian cancer patients, it enhances survival odds and improves life quality. This approval comes with a companion diagnostic to pinpoint eligible patients.

Which Companies Are Contributing Significantly To The Epithelial Ovarian Cancer Market Growth?

Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., Vivesto AB

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

Which Region Holds The Greatest Opportunity For Epithelial Ovarian Cancer Market Expansion?

North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20778&type=smp

Browse Through More Reports Similar to the Global Epithelial Ovarian Cancer Market 2025, By The Business Research Company

Ovarian Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report

Polycystic Ovarian Syndrome Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Ovarian Cancer Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model